EUROPEAN TRAINING CENTRES

 
Plaza de Cibeles
El Prado
Madrid

Nephrology Service
University Hospital Gregorio Marañón
Madrid, Spain

 

 

Peer Reviewed Publications in International Journals (only English) 2000-2002

Publications

Nephrol Dial Transplant 2001 Nov;16(11):2265-6 Acute renal failure after bacteraemia and endocarditis. Carretero D, Perez-Flores I, de Vinuesa SG, Luno J, Valderrabano F.

Nephrol Dial Transplant 2001;16 Suppl 1:78-81 Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.Garcia de Vinuesa S, Luno J, Gomez-Campdera F, Ridao N, Sanchez M, Dall'Anese C, Valderrabano F.

Nephrol Dial Transplant 2001;16 Suppl 1:70-3 Prevalence of hypertension in renal disease. Ridao N, Luno J, Garcia de Vinuesa S, Gomez F, Tejedor A, Valderrabano F.

Nefrologia 2001 Jan-Feb;21(1):9-15 [Risk factors in the development and progression of end-stage renal failure, the 21st century epidemic] Luno J, Garcia de Vinuesa S.

Nefrologia 2000 Mar-Apr;20(2):191-2 [Renal arteriography during heart catheterization: 2 explorations with the price of one] Gomez Campdera FJ, Luno J, Garcia de Vinuesa MS, Garcia E.

Nefrologia 2001 May-Jun;21(3):321-2 [Pre-dialysis vascular access. Does the evidence justify it?] Gomez Campdera FJ, Luno J, Garcia de Vinuesa S, Valderrabano F.

Nefrologia 2001 Mar-Apr;21(2):218-20 Dialysis inclusion criteria and early mortality] Gomez Campdera FJ, Luno J, Garcia de Vinuesa MS, Valderrabano F.

Nefrologia 2001 May-Jun;21(3):240-5 [Control of arterial pressure in diabetic nephropathy] Luno J, Garcia de Vinuesa S.

Nefrologia 2002;22(4):306-9 Perez Flores I, Luno J.

Nefrologia 2002;22 Suppl 1:30-5 [Renal and cardiovascular protection associated to antihypertensive treatment in the elderly] Luno J, Garcia de Vinuesa S.

Nephrol Dial Transplant 2002 Sep;17(9):1594-602Frequency of renal pathology in Spain 1994-1999. Rivera F, Lopez-Gomez JM, Perez-Garcia R.

Nefrologia 2001;21(6):538-47 Structural changes and vascular calcifications in uremia] Caramelo C, Goicoechea M, Albalate M, Nieto L, Melero R, Berlanga JR, Lopez MD, Gonzalez Pacheco F, Marron B, Alvarez Arroyo MV, Castilla MA, Yague S, Deudero JJ, Ortiz A

Kidney Int 2002 May;61(5):1845-52 AM3 (Inmunoferon) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Perez-Garcia R, Perez-Garcia A, Verbeelen D, Bernstein ED, Villarrubia VG, Alvarez-Mon M.

Nephrol Dial Transplant 2001;16 Suppl 1:98-101 Haemodialysis dose, extracellular volume control and arterial hypertension. Perez-Garcia R, Lopez-Gomez JM, Jofre R, Junco E, Valderrabano F.

Nephron 2000 Oct;86(2):222-3 -HuEPO resistance and dialysate chloramine contamination in patients on hemodialysis. Perez-Garcia R, Verde E, Sanz A, Valderrabano F.

Nephrol Dial Transplant 2000 Jun;15(6):760-4 Why and how to monitor bacterial contamination of dialysate? Perez-Garcia R, Rodriguez-Benitez PO.

Am J Kidney Dis 2001 Sep;38(3):443-64 Quality of life in end-stage renal disease patients. Valderrabano F, Jofre R, Lopez-Gomez JM.

J Am Soc Nephrol 2000 Feb;11(2):335-42 Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F.

Nephrol Dial Transplant 2001 Nov;16(11):2188-93 Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis. Goicoechea M, Caramelo C, Rodriguez P, Verde E, Gruss E, Albalate M, Ortiz A, Casado S, Valderrabano F.

Nephron 2001 Jun;88(2):170-3 Development of porphyria cutanea tarda in a hemodialysis patient after reactivation of hepatitis C virus infection. Albalate M, Farinas MC, Octavio JG, Perez JH, Goicoechea M, Caramelo C.

Am J Kidney Dis 2000 Jul;36(1):80-7 Antiplatelet therapy alters iron requirements in hemodialysis patients. Goicoechea M, Caramelo C, Ochando A, Andrea C, Garvia R, Ortiz A.

J Am Soc Nephrol 2000 Dec;11(12):2315-23 Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells. Hortelano S, Castilla M, Torres AM, Tejedor A, Bosca L.

Life Sci 2000;67(9):1003-13 Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Castilla MA, Caramelo C, Gazapo RM, Martin O, Gonzalez-Pacheco FR, Tejedor A, Bragado R, Arroyo MV.

Nefrologia 2002;22(2):98-103 Importance of the residual renal function in hemodialysis patients] Rodriguez Benitez P, Gomez Campdera FJ.

Nephrol Dial Transplant 2001;16 Suppl 1:74-7 Clinical characteristics of ischaemic renal disease. Alcazar JM, Marin R, Gomez-Campdera F, Orte L, Rodriguez-Jornet A, Mora-Macia J; Spanish Group of Ischaemic Nephrology (GEDENI)

Nephrol Dial Transplant 2001;16 Suppl 1:117-20 Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. Holgado R, Anaya F, Del Castillo D.

Rev Neurol 2000 Apr 1-15;30(7):601-5 Plasma immunoadsorption treatment of malignant multiple sclerosis with severe and prolonged relapses] de Andres C, Anaya F, Gimenez-Roldan S.

Nephrol Dial Transplant 2001;16 Suppl 1:121-4 Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Morales JM, Andres A, Rengel M, Rodicio JL.